Focused on rare liver diseases such as acute-on-chronic liver failure following its 2020 disappointment in NASH, Genfit looks to become sector leader in ACLF and other indications such as hepatic encephalopathy.

China's CSPC Pharmaceutical Group surprises by announcing investigator-initiated trial results for SYS6006, its mRNA COVID-19 vaccine candidate against the Omicron variant.

After CEO David Loew declared again that Ipsen would be very active in the dealmaking space, Ipsen is paying $45m upfront to access two immuno-oncology candidates from Marengo and bagged an ERK inhibitor from AGV Discovery.

As the Communist Party of China gears up for its once in every five years National Congress late this fall, the need for more novel drugs to help address the persistent coronavirus pandemic is rising amid the country’s strict “COVID Zero” policies.